Clarivate (CLVT) Projected to Post Earnings on Tuesday

Clarivate (NYSE:CLVT) is anticipated to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Clarivate to announce earnings of $0.1772 per share and revenue of $566.77 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Clarivate (NYSE:CLVT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. Clarivate had a positive return on equity of 9.15% and a negative net margin of 13.84%. The firm had revenue of $587.30 million for the quarter, compared to analyst estimates of $589.73 million. During the same period in the prior year, the firm posted $0.18 EPS. The company’s revenue for the quarter was down 5.5% on a year-over-year basis. On average, analysts expect Clarivate to post $0.67 EPS for the current fiscal year and $0.67 EPS for the next fiscal year.

Clarivate Stock Performance

Shares of NYSE CLVT opened at $1.87 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.85 and a quick ratio of 0.85. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -3.60 and a beta of 1.40. The stock’s fifty day moving average price is $1.84 and its two-hundred day moving average price is $2.26. Clarivate has a one year low of $1.42 and a one year high of $3.87.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CLVT shares. Stifel Nicolaus reduced their target price on shares of Clarivate from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a research report on Monday, September 21st. Citigroup lowered their price target on shares of Clarivate from $2.80 to $2.50 and set a “neutral” rating on the stock in a research report on Thursday, July 30th. Barclays dropped their price objective on shares of Clarivate from $2.50 to $2.00 and set an “underweight” rating for the company in a research note on Thursday, July 30th. Finally, William Blair downgraded shares of Clarivate to a “market perform” rating in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $3.02.

Insiders Place Their Bets

In other news, Director Andrew Snyder sold 2,489,618 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $1.94, for a total transaction of $4,829,858.92. Following the completion of the sale, the director directly owned 3,856,597 shares in the company, valued at approximately $7,481,798.18. This represents a 39.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kenneth Cornick bought 250,000 shares of Clarivate stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $1.85 per share, for a total transaction of $462,500.00. Following the completion of the acquisition, the director owned 2,000,000 shares in the company, valued at $3,700,000. This represents a 14.29% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 22.88% of the company’s stock.

About Clarivate

Clarivate Plc (NYSE:CLVT) provides analytics, data, and workflow solutions to organizations in academia, government, research, life sciences, and intellectual property. Its offerings are designed to help customers evaluate research, manage information, accelerate innovation, and support strategic decision-making.

The company’s products include Web of Science research databases and citation analytics, InCites research evaluation tools, Derwent innovation and patent intelligence services, and Cortellis life sciences and drug-development information.